Pfizer will merge its Upjohn off-patent unit with Mylan to create a new US-based generics and biosimilars giant, the two companies have confirmed.
Following a flurry of industry rumors, the firms announced on 29 July that they had signed a definitive agreement to combine Mylan with Upjohn